LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Kayser-Fleischer rings or bile pigment rings?

    Nagral, A / Jhaveri, A / Nalawade, S / Momaya, N / Chakkarwar, V / Malde, P

    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology

    2015  Volume 34, Issue 5, Page(s) 410–412

    MeSH term(s) Bile Pigments ; Copper ; Corneal Diseases ; Gastrointestinal Diseases ; Hepatolenticular Degeneration ; Humans
    Chemical Substances Bile Pigments ; Copper (789U1901C5)
    Language English
    Publishing date 2015-11-04
    Publishing country India
    Document type Letter ; Comment
    ZDB-ID 632595-6
    ISSN 0975-0711 ; 0254-8860
    ISSN (online) 0975-0711
    ISSN 0254-8860
    DOI 10.1007/s12664-015-0603-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2085: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Insulin glargine: a long acting insulin analog.

    Chakkarwar, P N / Manjrekar, N A

    Journal of postgraduate medicine

    2005  Volume 51, Issue 1, Page(s) 68–71

    Abstract: The main goal of treatment of diabetes mellitus (DM) is to maintain long term near normoglycemia. Insulin therapy plays a pivotal role in the management of DM. Most insulin preparations and insulin delivery systems, do not mimic the physiological insulin ...

    Abstract The main goal of treatment of diabetes mellitus (DM) is to maintain long term near normoglycemia. Insulin therapy plays a pivotal role in the management of DM. Most insulin preparations and insulin delivery systems, do not mimic the physiological insulin secretion in the body, leading to impaired metabolic control and increased hypoglycemic attacks. Insulin glargine is newer, long acting insulin analog with duration of action of 24 hr. It practically does not show any peak over its duration of action. In various clinical trials, it has shown comparable/better efficacy than the currently used insulin replacement therapies with no increased side effects. In the current scenario, though it is difficult to achieve an ideal replacement therapy, insulin glargine is definitely a positive step in that direction.
    MeSH term(s) Biotransformation ; Diabetes Mellitus/drug therapy ; Drug Interactions ; Humans ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Insulin/analogs & derivatives ; Insulin/pharmacology ; Insulin/therapeutic use ; Insulin Glargine ; Insulin, Long-Acting
    Chemical Substances Hypoglycemic Agents ; Insulin ; Insulin, Long-Acting ; Insulin Glargine (2ZM8CX04RZ)
    Language English
    Publishing date 2005-01
    Publishing country India
    Document type Journal Article ; Review
    ZDB-ID 410691-x
    ISSN 0022-3859
    ISSN 0022-3859
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 443: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Insulin glargine

    Chakkarwar P / Manjrekar N

    Journal of Postgraduate Medicine, Vol 51, Iss 1, Pp 68-

    A long acting insulin analog

    2005  Volume 71

    Keywords Medicine (General) ; R5-920 ; Medicine ; R ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Language English
    Publishing date 2005-01-01T00:00:00Z
    Publisher Medknow Publications
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article: Exemestane: a milestone against breast cancer.

    Shetty, Y C / Chakkarwar, P N / Acharya, S S / Rajadhyaksha, V D

    Journal of postgraduate medicine

    2005  Volume 53, Issue 2, Page(s) 135–138

    Abstract: Rapid advances in the treatment of breast cancer, especially in the form of hormone therapy have truly increased the hope of longer and better disease-free survival for these patients. Exemestane, a third generation aromatase inhibitor has been ... ...

    Abstract Rapid advances in the treatment of breast cancer, especially in the form of hormone therapy have truly increased the hope of longer and better disease-free survival for these patients. Exemestane, a third generation aromatase inhibitor has been extensively evaluated in metastatic as well as adjuvant therapy of breast cancer. It has also been evaluated for its safety profile, especially on bone and lipids. Exemestane provides hope to the patients with breast cancer both in early and metastatic disease. This review analyzes all the aspects of exemestane therapy.
    MeSH term(s) Androstadienes/adverse effects ; Androstadienes/therapeutic use ; Animals ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Aromatase Inhibitors/adverse effects ; Aromatase Inhibitors/therapeutic use ; Breast Neoplasms/drug therapy ; Female ; Humans
    Chemical Substances Androstadienes ; Antineoplastic Agents ; Aromatase Inhibitors ; exemestane (NY22HMQ4BX)
    Language English
    Publishing date 2005-06-16
    Publishing country India
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 410691-x
    ISSN 0022-3859
    ISSN 0022-3859
    DOI 10.4103/0022-3859.32218
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 443: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT study.

    Sharma, S K / Joshi, S R / Kumar, A / Unnikrishnan, A G / Hoskote, S S / Moharana, A K / Chakkarwar, P N / Vaz, J A

    The Journal of the Association of Physicians of India

    2008  Volume 56, Page(s) 859–863

    Abstract: ... of treatment in the Indian cohort (n = 3559) with type 2 diabetes mellitus who were inadequately controlled ... and -75.24 mg/dl) and post-prandial plasma glucose (-88.74 mg/dl and -119.16 mg/dl) (p < 0.001 ...

    Abstract Aim: The Physicians' Routine Evaluation of Safety and Efficacy of NovoMix 30 Therapy (PRESENT) study was done to assess the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in patients with type 2 diabetes mellitus in routine clinical practice.
    Materials and methods: This was a prospective, multicentric, multinational, observational study in type 2 diabetes patients. The patients were transferred to BIAsp 30 with or without oral antidiabetic drugs (OADs). We present the results of 6 months of treatment in the Indian cohort (n = 3559) with type 2 diabetes mellitus who were inadequately controlled on current treatment.
    Results: At three and six months, significant reductions from baseline were observed in the mean glycated haemoglobin (HbA1c) (-1.32% and -1.94%), fasting plasma glucose (-56.16 mg/dl and -75.24 mg/dl) and post-prandial plasma glucose (-88.74 mg/dl and -119.16 mg/dl) (p < 0.001). A significantly greater proportion of patients achieved target HbAlc of less than 7% at six months (31.1%), compared with baseline (3.1%), of which 70.4% did not report hypoglycaemia. The rate of total hypoglycaemia was reduced from 3.1 events per patient-year at baseline to 1.5 events per patient-year at end of the study. Episodes were mostly minor and diurnal. Except for two serious adverse drug reactions (ADRs) reported by one patient at 3 months, there were no reports of ADRs during the treatment period. More than 95% of patients and doctors were "very satisfied" or "satisfied" with BIAsp 30 treatment, compared to previous treatment.
    Conclusions: The use of BIAsp 30 monotherapy or in combination with OADs in clinical practice was effective and safe in poorly controlled Indian type 2 diabetes patients. Both patients and doctors showed a high degree of treatment satisfaction.
    MeSH term(s) Administration, Oral ; Biphasic Insulins ; Blood Glucose/drug effects ; Blood Glucose/metabolism ; Continental Population Groups ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/epidemiology ; Glycated Hemoglobin A/metabolism ; Humans ; Hypoglycemia/blood ; Hypoglycemia/chemically induced ; Hypoglycemia/drug therapy ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; India/epidemiology ; Injections, Subcutaneous ; Insulin/administration & dosage ; Insulin/analogs & derivatives ; Insulin/pharmacology ; Insulin/therapeutic use ; Insulin Aspart ; Insulin, Isophane ; Prospective Studies ; Treatment Outcome
    Chemical Substances Biphasic Insulins ; Blood Glucose ; Glycated Hemoglobin A ; Hypoglycemic Agents ; Insulin ; insulin aspart, insulin aspart protamine drug combination 30:70 ; Insulin, Isophane (53027-39-7) ; Insulin Aspart (D933668QVX)
    Language English
    Publishing date 2008-11
    Publishing country India
    Document type Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 800766-4
    ISSN 0004-5772
    ISSN 0004-5772
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 313: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top